Raw-Material Authentication Using a Handheld Raman Spectrometer - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Raw-Material Authentication Using a Handheld Raman Spectrometer
Using a handheld Raman spectrometer, the authors developed methods for 28 commonly used excipients and active ingredients.


Pharmaceutical Technology
Volume 3, Issue 32

Results and discussion


Table II: Measurement time averages (rounded to nearest second).
When authenticating material, the user selects the appropriate method from a menu on the instrument's display and enters the material identification number with the barcode reader or keypad. The operator directs the unit's laser aperture toward the sample and initiates the measurement. Once data collection begins, the instrument optimizes settings including exposure time, number of accumulations, and laser power to achieve acceptable SNR as quickly as possible. Table II shows the average measurement times required for each material. As demonstrated by the information in Table II, the average measurement times vary considerably depending on the characteristics of the material (Raman cross section, etc.). Specifically, the times range from 1 s to more than 6 min; however, the majority of materials were measured in less than 1 min. The individual measurement times (not shown) for the three units differ to some degree, as well, primarily because of environmental conditions during the measurement (sample positioning, ambient light, etc.).


Figure 6
As indicated in the experimental section, a p-value for each unknown-method pair was generated for measurements across all three test devices. The p-values, which indicate whether the measured spectrum is statistically different from the reference spectrum, were examined individually and were averaged for presentation purposes. Figure 6 shows data for each material– method pair. Note that the values shown range from p <10–15 to p >0.1. In normal application of the instrument, the result is a simple pass–fail determination. The unit's default threshold for "pass" is p ≥0.05. This indicates that the measured spectrum is statistically consistent with the reference spectrum given the uncertainty of the measurement.

The diagonal elements of Figure 6 represent cases in which the material was tested against the corresponding method, whereas the off-diagonal entries represent materials being tested by the "wrong" method. The dark-green squares on the diagonal show where the measured spectrum matched the corresponding reference spectrum with a p-value >0.1, which indicate that these materials easily pass as being consistent with the method reference spectrum. Two materials, ethyl cellulose and hydroxypropyl cellulose, resulted in average p-values in the range of 0.01 to 0.1 when tested against themselves. As also shown in Figure 6, examination of individual results from each of the three instruments revealed that these two samples, numbers 10 and 11 (indicated by daggers), were the only ones that resulted in differences in pass–fail decisions among the three test instruments. For ethyl cellulose, the p-values were 0.03, 0.06, and 0.04, and for hydroxypropyl cellulose, the p-values were 0.02, 0.05, and 0.11 across the three test units, respectively. Thus, both materials were very close to the borderline threshold of 0.05 and either just passed or just failed.


ADVERTISEMENT

blog comments powered by Disqus
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
What role should the US government play in the current Ebola outbreak?
Finance development of drugs to treat/prevent disease.
Oversee medical treatment of patients in the US.
Provide treatment for patients globally.
All of the above.
No government involvement in patient treatment or drug development.
Finance development of drugs to treat/prevent disease.
27%
Oversee medical treatment of patients in the US.
12%
Provide treatment for patients globally.
8%
All of the above.
46%
No government involvement in patient treatment or drug development.
7%
Jim Miller Outsourcing Outlook Jim MillerCMO Industry Thins Out
Cynthia Challener, PhD Ingredients Insider Cynthia ChallenerFluorination Remains Key Challenge in API Synthesis
Marilyn E. Morris Guest EditorialMarilyn E. MorrisBolstering Graduate Education and Research Programs
Jill Wechsler Regulatory Watch Jill Wechsler Biopharma Manufacturers Respond to Ebola Crisis
Sean Milmo European Regulatory WatchSean MilmoHarmonizing Marketing Approval of Generic Drugs in Europe
Seven Steps to Solving Tabletting and Tooling ProblemsStep 1: Clean
Legislators Urge Added Incentives for Ebola Drug Development
FDA Reorganization to Promote Drug Quality
FDA Readies Quality Metrics Measures
New FDA Team to Spur Modern Drug Manufacturing
Source: Pharmaceutical Technology,
Click here